Premier Biomedical, Inc. (OTCQB: "BIEI") announced the addition of Dr. James Frincke to their Scientific Advisory Board effective immediately. Dr. Frincke will report to co-founder and Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman.
James Frincke, PhD, is a Research & Development Consultant at Red Spot Biosciences, LLC, currently providing pro bono consultation to physicians globally to discover treatments for diseases, such as Crohn's, Rheumatoid Arthritis, Alzheimer's, Parkinson's and Type 1 Diabetes. With over 30 years of experience in the biotechnology industry, Dr. Frincke has successfully managed major development programs for all phases of pharmaceutical development. Dr. Frincke received his PhD and BS degrees in Organic Chemistry from the University of California, Davis and has performed postdoctoral work in the area of drug metabolism.
Prior to Dr. Frincke’s work as a consultant, he was VP of R&D Operations at Harbor Therapeutics, San Diego, CA, where he focused on treatments for age-related diseases. He is a world renowned pharmaceutical scientist and has raised hundreds of millions of dollars to fund new and groundbreaking small molecule compound (monoclonal antibody), biological, and cellular and gene therapies. Dr. Frincke is a prolific inventor with 24 US and 120 International patents to his credit. He has also published 75 peer reviewed journal articles and has submitted 32 new drug applications to the FDA.
Mitchell S. Felder, Co-Founder and Chairman of Premier Biomedical’s Scientific Advisory Board stated, "Dr. Frincke brings an outstanding level of drug development experience and business expertise to Premier. Together with the other distinguished members of our Scientific Advisory Board, Dr. Frincke will help guide and expedite the advancement of our R&D programs currently underway at the University of Texas at El Paso (UTEP), and other research partners, to combat breast and other forms of cancer, and other gene therapy related treatments for Amyotrophic Lateral Sclerosis (ALS), Muscular Dystrophy (MD) and Alzheimer’s Disease."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company's common stock trades on the Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150819005356/en/